Haemonetics Co. (NYSE:HAE) Shares Sold by California Public Employees Retirement System

California Public Employees Retirement System cut its stake in shares of Haemonetics Co. (NYSE:HAE) by 3.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 218,361 shares of the medical instruments supplier’s stock after selling 7,015 shares during the quarter. California Public Employees Retirement System owned about 0.43% of Haemonetics worth $17,050,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Whittier Trust Co. purchased a new stake in Haemonetics during the fourth quarter worth about $62,000. Parkside Financial Bank & Trust lifted its position in shares of Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock valued at $92,000 after acquiring an additional 240 shares during the period. AlphaQuest LLC boosted its stake in shares of Haemonetics by 36,520.0% during the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock worth $143,000 after acquiring an additional 1,826 shares in the last quarter. KBC Group NV grew its holdings in shares of Haemonetics by 54.6% in the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock worth $157,000 after acquiring an additional 712 shares during the period. Finally, iSAM Funds UK Ltd purchased a new position in Haemonetics in the 3rd quarter valued at approximately $204,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on HAE shares. JPMorgan Chase & Co. initiated coverage on Haemonetics in a research report on Friday, December 6th. They set an “overweight” rating and a $116.00 target price on the stock. Bank of America lowered shares of Haemonetics from a “neutral” rating to an “underperform” rating and decreased their price objective for the stock from $95.00 to $68.00 in a research report on Friday, February 7th. Barrington Research dropped their target price on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a report on Friday, February 7th. StockNews.com downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Saturday, February 15th. Finally, Needham & Company LLC dropped their price objective on shares of Haemonetics from $108.00 to $104.00 and set a “buy” rating for the company in a research note on Tuesday, March 18th. One analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $101.22.

Haemonetics Stock Down 2.3 %

Shares of NYSE HAE opened at $60.80 on Friday. The firm’s 50 day moving average price is $65.01 and its 200 day moving average price is $74.27. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. The firm has a market cap of $3.05 billion, a P/E ratio of 23.94, a price-to-earnings-growth ratio of 1.11 and a beta of 0.43. Haemonetics Co. has a 1 year low of $58.80 and a 1 year high of $97.97.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, sell-side analysts anticipate that Haemonetics Co. will post 4.55 earnings per share for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.